<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">ADMET DMPK</journal-id><journal-id journal-id-type="iso-abbrev">ADMET DMPK</journal-id><journal-id journal-id-type="pmc-domain-id">4169</journal-id><journal-id journal-id-type="pmc-domain">admet</journal-id><journal-id journal-id-type="publisher-id">ADMET</journal-id><journal-title-group><journal-title>ADMET &amp; DMPK</journal-title></journal-title-group><issn pub-type="epub">1848-7718</issn><publisher><publisher-name>International Association of Physical Chemists</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11661808</article-id><article-id pub-id-type="pmcid-ver">PMC11661808.1</article-id><article-id pub-id-type="pmcaid">11661808</article-id><article-id pub-id-type="pmcaiid">11661808</article-id><article-id pub-id-type="pmid">39713251</article-id><article-id pub-id-type="doi">10.5599/admet.2387</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Scientific Paper</subject></subj-group></article-categories><title-group><article-title>Pharmacokinetics and metabolism of ketoconazole after single ocular instillation in Sprague-Dawley rats</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Pu</surname><given-names initials="J">Jiang</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>He</surname><given-names initials="J">Jinsong</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Xue</surname><given-names initials="R">Ru</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gao</surname><given-names initials="R">Ruiqi</given-names></name></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yu</surname><given-names initials="Y">Yaoming</given-names></name></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Feng</surname><given-names initials="W">Wanyong</given-names></name><xref rid="cor1" ref-type="corresp">
<sup>*</sup>
</xref></contrib></contrib-group><aff><institution>Bioduro-Sundia</institution>, <addr-line>Shanghai, China</addr-line></aff><author-notes><corresp id="cor1">*Corresponding Author: E-mail: <italic toggle="yes"><email>wanyong.feng@bioduro-sundia.com</email>;</italic> Tel.: <phone>+86-021-31751005</phone></corresp></author-notes><pub-date pub-type="epub"><day>09</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><year>2024</year></pub-date><volume>12</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">477487</issue-id><fpage>943</fpage><lpage>955</lpage><history><date date-type="received"><day>03</day><month>8</month><year>2024</year></date><date date-type="rev-recd"><day>17</day><month>10</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>09</day><month>11</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>21</day><month>12</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-12-23 15:25:17.273"><day>23</day><month>12</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ADMET-12-2387.pdf"/><abstract><title>Abstract</title><sec><title>Background and purpose</title><p>Ketoconazole is limited to its conditioned oral use due to hepatic toxicity. Its ocular eye drop administration may be an option for mycotic keratitis treatment. Therefore, it is necessary to explore its pharmacokinetic and metabolic profile via topical ocular administration.</p></sec><sec><title>Experimental approach</title><p>Nine rats were dosed at 300 &#956;g/rat via topical ocular administration, and sacrificed at 5, 30, and 120 min with 3 rats/timepoint. Plasma, cornea, retina, and vitreous humour samples were collected, processed, and analysed.</p></sec><sec><title>Key results</title><p>Ketoconazole was quantified with a mean peak plasma concentration of 445 ng/mL at 5 min post-dose. In the rat ocular tissue, the mean ketoconazole concentration at 5 min post-dose was 423 &#956;g/g in the cornea, 4.96 &#956;g/g in the retina, and 1.19 &#956;g/g in the vitreous humour, respectively. The mean ketoconazole concentration in each matrix decreased from 5 to 120 min. The mean ketoconazole concentration at 120 min was 38.4 ng/mL in plasma, and 8.36, 0.0944, and 0.116 &#956;g/g in the cornea, retina, and vitreous humour, respectively. Pooled plasma, cornea, retina, and vitreous humour homogenates were used for metabolite identification. Nine metabolites were identified in rat plasma, and O-dealkylated metabolite (M3) and dehydrogenated metabolite (M11) were the top two, accounting for 5.0 and 5.8 % of the relative mass abundance. The metabolic pathways were O-dealkylation, mono-oxygenation, and dehydrogenation. Eleven metabolites were identified in the rat cornea, and two metabolites were identified in the rat retina and vitreous humour, respectively. The O-dealkylated and hydrogenated metabolite (M2) was a dominant metabolite in the cornea, retina, and vitreous humour, while M3 and M11 were the dominant metabolites in plasma.</p></sec><sec><title>Conclusion</title><p>Ketoconazole was a dominant component (&#8805; 98.5 %) in the cornea, retina, and vitreous humour, having higher concentrations in cornea than in plasma. M2 was identified as a dominant metabolite (1.1-1.2 %) in the cornea, retina, while M3 (5.0 %) and M11 (5.8 %) were identified as dominant metabolites in the plasma.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Plasma</kwd><kwd>cornea</kwd><kwd>retina</kwd><kwd>quantitation</kwd><kwd>metabolite identification</kwd><kwd>mass spectrometry</kwd></kwd-group><counts><fig-count count="5"/><table-count count="1"/><equation-count count="0"/><ref-count count="58"/><page-count count="13"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1-1"><title>Introduction</title><p>Mycotic keratitis is a common disease in ophthalmology. Its symptoms are not typical in the early stages. <italic toggle="yes">Fusarium</italic> and <italic toggle="yes">Curvularia</italic> are the major pathogens in river districts, and once infected, they could severely affect vision. Ketoconazole is a drug used in the management and treatment of fungal infections. As a dioxolane imidazole [<xref rid="ref1" ref-type="bibr">1</xref>,<xref rid="ref2" ref-type="bibr">2</xref>], ketoconazole inhibits sterol biosynthesis in the fungal membrane [<xref rid="ref3" ref-type="bibr">3</xref>]. This inhibition could deprive the fungal cell of its protective sterol membrane, making ketoconazole widely accepted and used as a broad-spectrum drug to treat mycotic keratitis.</p><p>Ketoconazole is a weak dibasic agent and requires acidity for dissolution and absorption. Its pharmacokinetics in humans has been widely studied and characterized. It reaches its maximum plasma concentration at 1-2 h and exhibits a biphasic elimination of 2 h during the first 10 h and 8 h thereafter [<xref rid="ref4" ref-type="bibr">4</xref>,<xref rid="ref5" ref-type="bibr">5</xref>]. CYP3A4 is the major enzyme involved in the metabolism of ketoconazole. The major identified metabolic pathways are oxidation and degradation of the imidazole and piperazine rings by hepatic microsomal enzymes. In addition, oxidative <italic toggle="yes">O</italic>-dealkylation and aromatic hydroxylation do occur. Many drug-drug interaction studies of ketoconazole <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> human systems have been reported, and such information is well documented [<xref rid="ref4" ref-type="bibr">4</xref>,<xref rid="ref5" ref-type="bibr">5</xref>]. Ketoconazole has also been recognized as a specific CYP3A4/5 inhibitor and a strong clinical CYP3A4 inhibitor, as well as an inhibitor of P-gp, BCRP, OATPs, OAT3, OCT2, and MATEs transporters, clinical P-gp inhibitor for drug-drug interaction studies recommended by regulatory agencies [<xref rid="ref6" ref-type="bibr">6</xref>]. Orally administered ketoconazole is limited in clinical use due to metabolism-related hepatotoxicity [<xref rid="ref7" ref-type="bibr">7-10</xref>]. <italic toggle="yes">N</italic>-deacetyl ketoconazole (DAK), as a primary metabolite of ketoconazole, is believed to undergo metabolism through flavin-containing monooxygenase (FMO) and may be transformed into a potentially toxic dialdehyde [<xref rid="ref11" ref-type="bibr">11-14</xref>]. Rodriguez <italic toggle="yes">et al.</italic> [<xref rid="ref11" ref-type="bibr">11</xref>] studied the toxicity of DAK and demonstrated that it was more metabolically cytotoxic than ketoconazole. Afterwards, Haegler <italic toggle="yes">et al.</italic> [<xref rid="ref12" ref-type="bibr">12</xref>] studied the mitochondrial toxic effects of ketoconazole at concentrations easily reached in vivo. They found that cytotoxicity and adenosine triphosphate (ATP) depletion were more pronounced in cells with mitochondrial damage. In July, 2013, the US FDA released a safety announcement regarding the use of oral ketoconazole tablets and their potential adverse drug reactions. It was advised that ketoconazole should not be used as a first-line treatment for fungal infections due to the risk of potentially serious drug-drug interactions [<xref rid="ref15" ref-type="bibr">15-17</xref>]. The European Medicines Agency had also proposed limiting the use of oral ketoconazole in fungal infections due to the same risk [<xref rid="ref18" ref-type="bibr">18</xref>,<xref rid="ref19" ref-type="bibr">19</xref>].</p><p>Unlike oral administration, local drug administration, such as intramuscular, intraperitoneal, subcutaneous, transdermal, and topical ocular administration, can be an alternative approach to avoid first-pass intestinal and hepatic metabolism and associated drug-drug interactions and achieve higher exposure levels in target organs due to a lower metabolic loss of the drug. Ocular drug delivery has been an active area in the use of old drugs and new ophthalmic drug discovery and development [<xref rid="ref20" ref-type="bibr">20-23</xref>]. Fundamental drug-metabolizing enzymes, uptake, and efflux transport information in different locations of the eyes in animals and humans (cornea, lens, iris, retina, vitreous humour, <italic toggle="yes">etc</italic>.) are very limited. The eye is a complex organ with protective anatomy and physiology. Understanding pharmacokinetics and drug metabolism in ocular tissues is a major challenge because of the complex anatomy and dynamic physiological barrier of the eye. Ocular drug metabolism in the eye is crucial for ocular therapeutics to facilitate the risk assessment and the development of potential drug candidates in the clinical stage. In the discovery stage, rabbits and other less common species, such as dogs, monkeys, and rats, are also used to study ocular pharmacokinetics and drug metabolism [<xref rid="ref24" ref-type="bibr">24-28</xref>]. As shown in a recent mini-review, twenty-six enzymes, including eleven human CYP enzymes (CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2E1, CYP2D6, CYP3A4, CYP3A5) and other phase I/II enzymes in cornea, lens, iris, ciliary body, retina, choroid, retinal pigment epithelium, optic nerve and sclera, and 38 uptake and efflux transporters including MATE1-2, PEPT1-2, P-gp, BCRP, and MRP1-6 in cornea, lens, iris, ciliary body, retina and choroid, were reported [<xref rid="ref29" ref-type="bibr">29</xref>].</p><p>Although the metabolism of ketoconazole after oral administration in humans is well studied, it is not well explored in the eye in any preclinical species or humans. In rats, ketoconazole has been well studied as a substrate <italic toggle="yes">in vitro</italic> system [<xref rid="ref30" ref-type="bibr">30</xref>,<xref rid="ref31" ref-type="bibr">31</xref>] and <italic toggle="yes">in vivo</italic> systems [<xref rid="ref30" ref-type="bibr">30-32</xref>] or as a rat CYP3A inhibitor <italic toggle="yes">in vitro</italic> systems [<xref rid="ref33" ref-type="bibr">33-35</xref>] and <italic toggle="yes">in vivo</italic> systems [<xref rid="ref36" ref-type="bibr">36-57</xref>]. Cirello <italic toggle="yes">et al.</italic> [<xref rid="ref58" ref-type="bibr">58</xref>] reported that in rat, rabbit, and human ocular and liver S9 fractions, eleven metabolites were identified, six metabolites were found in rat ocular, whereas eight were present in rabbit and human ocular S9 fractions. Three more metabolites were found in rat liver than in rat ocular S9 fractions. Metabolic pathways in rabbit and human ocular fractions suggested the formation of reactive intermediates in rabbit and human liver, and ocular S9 incubations. Bioactivation was found to occur via iminium ion in both human and rabbit ocular S9 fractions, and the reactive intermediates were identified using potassium cyanide trapping methodology. To our best knowledge, no <italic toggle="yes">in vivo</italic> ocular metabolism of ketoconazole in rats has been reported, although it has been extensively investigated following oral or intravenous administration in rats. To understand the metabolic disposition of ketoconazole in different eye tissues, we chose the rat to study the ocular metabolism of ketoconazole in plasma, cornea, retina, and vitreous humour after a single topical instillation administration.</p></sec><sec id="sec1-2"><title>Experimental</title><sec id="sec2-1"><title>Chemicals and reagents</title><p>Ketoconazole (SLCC4160) was purchased from Sigma in USA; (2-Hydroxypropyl)-&#946;-cyclodextrin (HP&#946;CD, WXBC0083V) was also obtained from Sigma in USA; Distilled H<sub>2</sub>O (20190802 C) was purchased from Watsons in China.</p></sec><sec id="sec2-2"><title>Formulation preparation</title><p>Ketoconazole was weighed and dissolved in a 4 mL glass vial, and then 0.083 mL of water was added and vortexed. The mixture was stirred at 40 &#176;C. Subsequently, 0.040 mL of 1 M hydrochloric acid was added, and the mixture was stirred at 40 &#176;C until it was completely dissolved. 0.250 mL of hydroxypropyl beta-cyclodextrin (HP&#946;CD) was added and vortexed and stirred at 40 &#176;C until clear. 0.005 mL of 1 M sodium hydroxide was added to adjust the pH to 6.5-7.0 while stirring magnetically at 40 &#176;C, and 0.038 mL of water was added, vortexed, and stirred at 40 &#176;C until clear. At last, a 30 mg/mL ketoconazole clear solution was prepared in 12.5 % HP&#946;CD in water.</p></sec><sec id="sec2-3"><title>Animal administration</title><p>All procedures performed on the animals were in accordance with regulations and established guidelines and were reviewed and approved by an Institutional Animal Care and Use Committee through an ethical review process. Nine male Sprague Dawley rats were 7 to 9 weeks old and purchased from Vital River (Zhejiang, China). Rats were allowed to acclimate approximately one week before treatment, with water and food available <italic toggle="yes">ad libitum</italic> throughout the acclimation and experimental periods.</p><p>Nine rats were randomly divided into three groups and their body weights were recorded from 254 to 281 g. A 5 &#956;L ketoconazole solution (30 mg/mL in 12.5 % HP&#946;CD ) was instilled in both eyes, delivering 150 &#956;g per eye (total 300 &#956;g per rat) over 30 seconds. Rats were sacrificed at 5, 30 and 120 min post-dose (<italic toggle="yes">n</italic> = 3 per time point). Cornea, retina, and vitreous humour samples were collected, washed in saline three times and weighed, while blood samples were taken from the heart puncture. Tissue samples were initially stored on dry ice, while the blood samples were centrifuged at 4 &#176;C and 6000 rpm for 10 min. Subsequently, the plasma samples were prepared and also stored on dry ice. Ultimately, all samples were cryopreserved in a -80 &#176;C freezer after harvest.</p></sec><sec id="sec2-4"><title>Tissues homogenization and treatment</title><p>All tissue samples were removed from the -80 &#176;C freezer, thawed on ice, and 0.200 mL of 75 % acetonitrile was added to each tissue. Each tissue was then homogenized using an Ultrasonic Cell Crusher for 5 seconds. The cornea and retina homogenates were sonicated for 10 min, while the vitreous was sonicated for 30 min at 0 &#176;C prior to bioanalysis. The ocular tissue homogenates were stored in a -80 &#176;C freezer before bioanalysis.</p><p>All samples underwent protein precipitation for pharmacokinetic analysis. Plasma and three types of tissue homogenate samples (50 &#956;L each) were treated with 5 &#956;L of methanol and then quenched with a 200 &#956;L methanol and acetonitrile mixture (1:1, v/v) containing 50 ng/mL terfenadine as an internal standard (ISTD). After vortexing for 1 min and centrifuging at 4000 rpm for 15 min, the supernatant was transferred and diluted 10-fold with a methanol/water solution (1:1, v/v, containing 0.1 % formic acid) for LC-MS/MS analysis. The working solution was prepared with a concentration range of 50.0 to 100,000 ng/mL. The ketoconazole standard curve for corneal homogenates ranged from 5.00 to 10,000 ng/mL, whereas for retina and vitreous humour homogenates, it ranged from 1.00 to 2,000 ng/mL.</p><p>Rat plasma (400 RL, 44.4 LL/rat at each time point) was pooled from 3-time points utilizing the equal volume method and subsequently precipitated with acetonitrile containing 0.1 % formic acid at a ratio of 1:3. Homogenate samples of rat cornea, retina, and vitreous humour (600 L, 66.7 LL /rat) were pooled from three time points individually utilizing the equal volume and transferred into a 15 mL centrifuge tube and subjected to precipitation with acetonitrile containing 0.1 % formic acid at the same ratio of 1:3. Following centrifugation, the supernatant was evaporated under a stream of nitrogen gas. The residues from plasma and rat retina were reconstituted with 150 L of 10 % acetonitrile in H<sub>2</sub>O (with 0.1 % formic acid), while the residues from the rat cornea and vitreous humour were reconstituted with 100 L of 10 % acetonitrile in H<sub>2</sub>O (0.1 % formic acid). Four types of blank samples were processed in a similar manner. Ultimately, 10,L samples of each tissue were injected for analysis using the Ultimate 3000-Q-Exactive Plus system.</p></sec><sec id="sec2-5"><title>Liquid chromatography-mass spectrometry analysis</title><p>The quantitative sample analysis was performed on a Shimadzu LC-20AD (Shimadzu, Japan) - API 4000 mass spectrometer (SCIEX, Canada). The chromatographic separation of analytes from the matrix was achieved on a Kinetex 2.6 &#956;m C18 100A column (3 30 mm) at room temperature with a flow rate of 0.7 mL/min. For plasma analysis, mobile phase A consisted of 5 mM ammonium acetate in distilled water (with 0.05 % formic acid), and mobile phase B consisted of acetonitrile (with 0.1 % formic acid). A step time gradient started by maintaining 15 % mobile phase B for 0.4 min, transitioning from 15 to 95 % mobile phase B over 1.8 min, holding at 95 % mobile phase B for 0.3 min, then returning to 15 % B in 0.01 min and re-equilibrating for 0.49 min. For the cornea, retina, and vitreous humour, a step time gradient started by maintaining 15 % mobile phase B for 0.4 min, transitioning from 15 to 95 % mobile phase B over 0.8 min, maintaining 95 % mobile phase B for 0.6 min, then returning to 15 % B in 0.01 min and re-equilibrating for 0.69 min. Ketoconazole was detected and quantified by performing positive-ion electrospray tandem mass spectrometry at 4500 V and 550 &#176;C, with multiple reaction monitoring modes of ion transition <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 531.2 to 489.2 for ketoconazole and <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 472.4 to 436.4 for terfenadine (ISTD).</p><p>The metabolite identification and analysis were conducted on an Ultimate 3000 - Q-Exactive plus high-resolution mass spectrometer (Thermo Fisher Scientific, Germany), ketoconazole and its metabolites were injected and separated using an ACQUITY UPLC&#174; HSS T3 column (1.8 &#956;m, 2.1&#215;100 mm) at room temperature with a flow rate of 0.3 mL/min. Mobile phase A consisted of water containing 0.1 % formic acid, while mobile phase B consisted of acetonitrile with 0.1 % formic acid. Chromatographic separation was achieved with a step time gradient by maintaining 5 % mobile phase B for 1.0 min, increasing from 5 to 25 % mobile phase B over 5.0 min, further increasing from 25 to 40 % mobile phase B over 8.0 min, then from 40 to 95 % mobile phase B over 3.0 min, maintaining 95 % mobile phase B for 2.0 min, and finally returning to 5 % B in 0.1 min and re-equilibrating for 2.9 min. Mass scanning was performed on the Q-Exactive Plus using positive-ion full MS/dd-MS2 mode with a range from <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 80 to 900. The collision energy was set at 30, 40 and 50 eV. The mass resolution was set as 70,000 for full MS, and 17,500 for dd-MS2 scans, and the mass error limit was set as 5.0 ppm.</p></sec></sec><sec id="sec1-3"><title>Results and discussion</title><sec id="sec2-6"><title>Pharmacokinetics characteristics</title><p>As shown in the left plot in <xref rid="fig001" ref-type="fig">Figure 1</xref>, ketoconazole concentrations were measured in plasma, cornea, retina, and vitreous humour at 5, 30 and 120 min after topical ocular administration in each eye. In rat plasma, the mean concentration was determined to be 0.445 &#956;g/mL at 5 min and then decreased over time. In rat cornea, the mean concentration was found to be extremely high at 416 &#956;g/g in the left eye and 430 &#956;g/g in the right eye at 5 min post-dose. In rat retina samples, the mean concentration was 0.439 &#956;g/g in the left eye and 0.552 &#956;g/g in the right eye at 5 min post-dose. Similar to rat retina, the mean concentration in rat vitreous humour was 1.12 &#956;g/g in the left eye and 1.18 &#956;g/g in the right eye at 5 min post-dose. The mean ketoconazole concentration in each tissue decreased from 5 to 120 min. The mean concentration of left and right eye tissue at 30 min post-dose was 0.303 &#956;g/mL in plasma, and 113, 1.47 and 0.713 &#956;g/g in cornea, retina, and vitreous humour, respectively. At 120 min post-dose, it was 0.0384 &#956;g/mL in plasma and 8.36, 0.0944 and 0.116 &#956;g/g in cornea, retina, and vitreous humour, respectively.</p><fig position="float" id="fig001" orientation="portrait"><label>Figure 1.</label><caption><p>Ketoconazole concentration in ocular tissue and plasma (a) and ratios of ocular tissue to plasma concentration (b)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ADMET-12-2387-g001.jpg"/></fig><p>Ketoconazole exhibited higher concentrations in the cornea, retina, and vitreous humour compared to plasma following topical ocular administration. As illustrated in <xref rid="fig001" ref-type="fig">Figure 1b</xref>, ketoconazole showed the highest tissue/plasma ratios in the cornea. Similarly, the retina and vitreous humour also demonstrated relatively elevated tissue/plasma ratios. This finding suggested that ketoconazole was readily accessible to the cornea following ocular administration. In an early study in rabbits [<xref rid="ref36" ref-type="bibr">36</xref>], a low ocular tissue/serum ratio was observed following the oral administration of ketoconazole at 43.5 mg/kg. Ketoconazole serum concentrations ranged from 5.00 to 10.0 &#956;g/mL, while corneal and vitreous humour concentrations were detectable and ranged from 0 to 0.0400 &#956;g/mL within four hours post-dose, respectively. A different administration route may result in different ocular tissue/plasma or ocular tissue/serum ratios.</p></sec><sec id="sec2-7"><title>Metabolites identification and profiling</title><p>In <xref rid="fig002" ref-type="fig">Figure 2</xref>, ketoconazole showed a protonated molecular ion [M+H]<sup>+</sup> at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 531.1551 (~1.9 ppm). The collision-induced dissociation (CID) product ion spectrum showed characteristic fragment ions <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 82.0530, 112.0759, 177.1020, 219.1126, 255.0083, 311.0338, 446.1033 and 489.1448. The LC retention time was 13.06 min. As shown in <xref rid="fig003" ref-type="fig">Figure 3</xref> and <xref rid="table001" ref-type="table">Table 1</xref>, a total of thirteen metabolites were eluted from 8.91 to 16.34 min and extracted within a mass error of 5 ppm, most metabolites were eluted earlier than ketoconazole and turned out to be much more polar compounds.</p><fig position="float" id="fig002" orientation="portrait"><label>Figure 2.</label><caption><p>Collision-induced dissociation spectrum of ketoconazole (CE = 40 eV)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ADMET-12-2387-g002.jpg"/></fig><fig position="float" id="fig003" orientation="portrait"><label>Figure 3.</label><caption><p>Selected ion chromatogram of ketoconazole and its metabolites</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ADMET-12-2387-g003.jpg"/></fig><table-wrap position="float" id="table001" orientation="portrait"><label>Table 1.</label><caption><p>Observed metabolites of ketoconazole in rat plasma and ocular tissues after eye drop administration</p></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="middle" rowspan="2" colspan="1">MET#</th><th align="center" valign="middle" rowspan="2" colspan="1">RT, min</th><th align="center" valign="middle" colspan="2" rowspan="1"><italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> (+)</th><th align="center" valign="middle" rowspan="2" colspan="1">Mass error, ppm</th><th align="center" valign="middle" rowspan="2" colspan="1">Metabolite pathway</th><th align="center" valign="middle" colspan="4" rowspan="1">Relative peak area abundance, %</th><th align="center" valign="middle" rowspan="2" colspan="1">Ref.</th></tr><tr><th align="center" valign="middle" rowspan="1" colspan="1">Theoretica</th><th align="center" valign="middle" rowspan="1" colspan="1">Detected</th><th align="center" valign="middle" rowspan="1" colspan="1">COR</th><th align="center" valign="middle" rowspan="1" colspan="1">RET</th><th align="center" valign="middle" rowspan="1" colspan="1">VH</th><th align="center" valign="middle" rowspan="1" colspan="1">PLA</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">M1</td><td align="center" valign="middle" rowspan="1" colspan="1">8.91</td><td align="center" valign="middle" rowspan="1" colspan="1">547.1510</td><td align="center" valign="middle" rowspan="1" colspan="1">547.1500</td><td align="center" valign="middle" rowspan="1" colspan="1">-1.8</td><td align="center" valign="middle" rowspan="1" colspan="1">Mono-oxygenation</td><td align="center" valign="middle" rowspan="1" colspan="1">D</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">D</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="ref55" ref-type="bibr">55</xref>,<xref rid="ref56" ref-type="bibr">56</xref>,<xref rid="ref58" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">M2</td><td align="center" valign="middle" rowspan="1" colspan="1">9.16</td><td align="center" valign="middle" rowspan="1" colspan="1">329.0454</td><td align="center" valign="middle" rowspan="1" colspan="1">329.0446</td><td align="center" valign="middle" rowspan="1" colspan="1">-2.4</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">O</italic>-dealkylation and hydrogenation</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1</td><td align="center" valign="middle" rowspan="1" colspan="1">1.2</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="ref55" ref-type="bibr">55</xref>,<xref rid="ref56" ref-type="bibr">56</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">M3</td><td align="center" valign="middle" rowspan="1" colspan="1">9.44</td><td align="center" valign="middle" rowspan="1" colspan="1">343.0247</td><td align="center" valign="middle" rowspan="1" colspan="1">343.0242</td><td align="center" valign="middle" rowspan="1" colspan="1">-1.5</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">O</italic>-dealkylation and mono-oxygenation</td><td align="center" valign="middle" rowspan="1" colspan="1">D</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">5.0</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="ref56" ref-type="bibr">56</xref>,<xref rid="ref58" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">M4 (DAK)</td><td align="center" valign="middle" rowspan="1" colspan="1">9.56</td><td align="center" valign="middle" rowspan="1" colspan="1">489.1455</td><td align="center" valign="middle" rowspan="1" colspan="1">489.1449</td><td align="center" valign="middle" rowspan="1" colspan="1">-1.2</td><td align="center" valign="middle" rowspan="1" colspan="1">Hydrolysis</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="ref11" ref-type="bibr">11</xref>,<xref rid="ref13" ref-type="bibr">13</xref>,<xref rid="ref30" ref-type="bibr">30</xref>,<xref rid="ref55" ref-type="bibr">55</xref>,<xref rid="ref56" ref-type="bibr">56</xref>,<xref rid="ref58" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">M5</td><td align="center" valign="middle" rowspan="1" colspan="1">9.73</td><td align="center" valign="middle" rowspan="1" colspan="1">505.1404</td><td align="center" valign="middle" rowspan="1" colspan="1">505.1399</td><td align="center" valign="middle" rowspan="1" colspan="1">-1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">Hydrolysis and mono-oxygenation</td><td align="center" valign="middle" rowspan="1" colspan="1">D</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="ref55" ref-type="bibr">55</xref>,<xref rid="ref56" ref-type="bibr">56</xref>,<xref rid="ref58" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">M6</td><td align="center" valign="middle" rowspan="1" colspan="1">11.41</td><td align="center" valign="middle" rowspan="1" colspan="1">480.1451</td><td align="center" valign="middle" rowspan="1" colspan="1">480.1440</td><td align="center" valign="middle" rowspan="1" colspan="1">-2.3</td><td align="center" valign="middle" rowspan="1" colspan="1">Ring-opening <italic toggle="yes">N</italic>-dealkylation</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="ref56" ref-type="bibr">56</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">M7</td><td align="center" valign="middle" rowspan="1" colspan="1">11.92</td><td align="center" valign="middle" rowspan="1" colspan="1">545.1353</td><td align="center" valign="middle" rowspan="1" colspan="1">545.1343</td><td align="center" valign="middle" rowspan="1" colspan="1">-1.8</td><td align="center" valign="middle" rowspan="1" colspan="1">Mono-oxygenation and dehydrogenation</td><td align="center" valign="middle" rowspan="1" colspan="1">D</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="ref55" ref-type="bibr">55</xref>,<xref rid="ref56" ref-type="bibr">56</xref>,<xref rid="ref58" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">M8</td><td align="center" valign="middle" rowspan="1" colspan="1">11.98</td><td align="center" valign="middle" rowspan="1" colspan="1">547.1510</td><td align="center" valign="middle" rowspan="1" colspan="1">547.1531</td><td align="center" valign="middle" rowspan="1" colspan="1">3.8</td><td align="center" valign="middle" rowspan="1" colspan="1">Mono-oxygenation</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="ref55" ref-type="bibr">55</xref>,<xref rid="ref56" ref-type="bibr">56</xref>,<xref rid="ref58" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">M9</td><td align="center" valign="middle" rowspan="1" colspan="1">12.56</td><td align="center" valign="middle" rowspan="1" colspan="1">545.1353</td><td align="center" valign="middle" rowspan="1" colspan="1">545.1337</td><td align="center" valign="middle" rowspan="1" colspan="1">-2.9</td><td align="center" valign="middle" rowspan="1" colspan="1">Mono-oxygenation and dehydrogenation</td><td align="center" valign="middle" rowspan="1" colspan="1">D</td><td align="center" valign="middle" rowspan="1" colspan="1">D</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="ref55" ref-type="bibr">55</xref>,<xref rid="ref56" ref-type="bibr">56</xref>,<xref rid="ref58" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">M10</td><td align="center" valign="middle" rowspan="1" colspan="1">13.05</td><td align="center" valign="middle" rowspan="1" colspan="1">547.1510</td><td align="center" valign="middle" rowspan="1" colspan="1">547.1496</td><td align="center" valign="middle" rowspan="1" colspan="1">-2.6</td><td align="center" valign="middle" rowspan="1" colspan="1">Mono-oxygenation</td><td align="center" valign="middle" rowspan="1" colspan="1">D</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="ref55" ref-type="bibr">55</xref>,<xref rid="ref56" ref-type="bibr">56</xref>,<xref rid="ref58" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">KCZ</td><td align="center" valign="middle" rowspan="1" colspan="1">13.06</td><td align="center" valign="middle" rowspan="1" colspan="1">531.1560</td><td align="center" valign="middle" rowspan="1" colspan="1">531.1550</td><td align="center" valign="middle" rowspan="1" colspan="1">-1.9</td><td align="center" valign="middle" rowspan="1" colspan="1">--</td><td align="center" valign="middle" rowspan="1" colspan="1">98.3</td><td align="center" valign="middle" rowspan="1" colspan="1">98.8</td><td align="center" valign="middle" rowspan="1" colspan="1">99.4</td><td align="center" valign="middle" rowspan="1" colspan="1">85.4</td><td align="center" valign="middle" rowspan="1" colspan="1">--</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">M11</td><td align="center" valign="middle" rowspan="1" colspan="1">15.83</td><td align="center" valign="middle" rowspan="1" colspan="1">529.1404</td><td align="center" valign="middle" rowspan="1" colspan="1">529.1390</td><td align="center" valign="middle" rowspan="1" colspan="1">-2.6</td><td align="center" valign="middle" rowspan="1" colspan="1">Dehydrogenation</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">5.8</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="ref55" ref-type="bibr">55</xref>,<xref rid="ref58" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">M12</td><td align="center" valign="middle" rowspan="1" colspan="1">15.88</td><td align="center" valign="middle" rowspan="1" colspan="1">545.1353</td><td align="center" valign="middle" rowspan="1" colspan="1">545.1343</td><td align="center" valign="middle" rowspan="1" colspan="1">-1.8</td><td align="center" valign="middle" rowspan="1" colspan="1">Mono-oxygenation and dehydrogenation</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">1.6</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="ref55" ref-type="bibr">55</xref>,<xref rid="ref56" ref-type="bibr">56</xref>,<xref rid="ref58" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">M13</td><td align="center" valign="middle" rowspan="1" colspan="1">16.34</td><td align="center" valign="middle" rowspan="1" colspan="1">545.1353</td><td align="center" valign="middle" rowspan="1" colspan="1">545.1345</td><td align="center" valign="middle" rowspan="1" colspan="1">-1.5</td><td align="center" valign="middle" rowspan="1" colspan="1">Mono-oxygenation and dehydrogenation</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="ref55" ref-type="bibr">55</xref>,<xref rid="ref56" ref-type="bibr">56</xref>,<xref rid="ref58" ref-type="bibr">58</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>Note: KCZ - Ketoconazole; MET# - metabolite identity number; COR - cornea; RET - retina; VH - vitreous humour; PLA - plasma; RT - retention time; D - detected in trace amount (the relative abundance was less than 0.1 %); ND - not detected; RT - retention time; DAK - deacetyl ketoconazole; The relative abundances of the parent and metabolites were calculated based on their selected ion chromatographic peak areas.</p></fn></table-wrap-foot></table-wrap><p>Several metabolites were identified by the mass defect method based on the characteristic fragment ions compared with ketoconazole, as shown in <xref rid="fig004" ref-type="fig">Figure 4</xref>. M1 showed a protonated molecular ion at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 547.1500, its characteristic ions were <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 255.0079, 471.1104 and 505.1397. M8 showed a protonated molecular ion at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 505.1496, its characteristic ion 505.1415. M10 showed a protonated molecular ion at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 547.1409, its characteristic ion was <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 505.1351. The addition of 16 amu to parent fragment ions indicated M1, M8 and M10 were mono-oxygenation metabolites. M4 showed a protonated molecular ion at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 489.1449, its CID product ion spectrum displayed fragment ions at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 82.0531, 136.0756, 178.1099 and 446.1021, the loss of 42 amu from parent ion indicated it was a hydrolysis metabolite, also called as a deacetyl-ketoconazole (DAK). M5 showed a protonated molecular ion at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 505.1399, its CID product ion spectrum displayed fragment ions at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 255.0083, 267.0082 and 420.0872, the addition of 16 amu to M4 indicated it was a metabolite of hydrolysis and mono-oxygenation. M11 exhibited a protonated molecular ion at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 529.1390, its CID product ion spectrum displayed fragment ions at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 175.0864, 218.1046, 255.0091 and 487.1302, the loss of 2 amu from parent fragment ions indicated it was a dehydrogenation metabolite.</p><fig position="float" id="fig004" orientation="portrait"><label>Figure 4.</label><caption><p>MS/MS spectra of metabolites of ketoconazole in rat cornea, retina, vitreous humour and plasma</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ADMET-12-2387-g004.jpg"/></fig><p>M7 showed a protonated molecular ion at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 545.1343, its CID product ion spectrum displayed fragment ions at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 255.0082, 421.0720 and 503.1211. M9 showed a protonated molecular ion at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 545.1337, its CID product ion spectrum displayed fragment ions at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 255.0081, 329.0440, 487.0919 and 503.1187 M12 showed a protonated molecular ion at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 545.1343, its CID product ion spectrum displayed fragment ions at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 244.0051, 311.0325 and 503.1207. M13 exhibited a protonated molecular ion at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 545.1345, its CID product ion spectrum displayed fragment ions at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 244.0050, 311.0336 and 503.1237. The addition of 14 amu to parent fragment ions indicated that M7, M9, M12, and M13 were metabolites of mono-oxygenation and dehydrogenation.</p><p>The other metabolites were elucidated according to their characteristic fragment ions and <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> accuracy. M2 showed a protonated molecular ion at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 329.0446, its CID product ions were <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 158.9761 and 274.9870, the loss of 202 amu from parent ion indicated it was a metabolite of <italic toggle="yes">O</italic>-dealkylation and hydrogenation, this metabolite was also determined in rat, rabbit and human liver S9 fractions by Cirello <italic toggle="yes">et al.</italic> [<xref rid="ref55" ref-type="bibr">55</xref>] according to the same fragment (<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 255.0086). M3 showed a protonated molecular ion at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 343.0242, its CID product ion spectrum showed fragment ions at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 158.9763, 255.0086 and 274.9870, the loss of 188 amu to the parent ion, indicating that it was a metabolite of <italic toggle="yes">O</italic>-dealkylation and mono-oxygenation. M6 showed a protonated molecular ion at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 480.1440, its CID product ion spectrum displayed fragment ions at <italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 112.0761, 219.1127, 421.1087 and 463.1176, the loss of 51 amu from parent ion indicated it was a metabolite of ring-opening <italic toggle="yes">N</italic>-dealkylation.</p><p>As indicated in <xref rid="fig003" ref-type="fig">Figure 3</xref> and <xref rid="table001" ref-type="table">Table 1</xref>, ketoconazole was slowly eliminated in pooled plasma, cornea, retina, and vitreous humour samples within 120 min after topical ocular administration, and it was still a dominant component. In rat plasma, nine metabolites of ketoconazole were identified, the top two metabolites were M3 and M11, accounting for 5.0 and 5.8 % of the total mass abundance, its biotransformation involved <italic toggle="yes">O</italic>-dealkylation, mono-oxygenation and dehydrogenation. In the rat cornea, eleven metabolites were identified. The primary metabolite was M2, which underwent biotransformation through <italic toggle="yes">O</italic>-dealkylation and hydrogenation. In the rat retina, two metabolites were identified, with M2 being the top one. In the vitreous humour, two metabolites were identified, with M2 remaining the primary one.</p><p>As summarized in <xref rid="fig005" ref-type="fig">Figure 5</xref> and <xref rid="table001" ref-type="table">Table 1</xref>, observed metabolic pathways included <italic toggle="yes">O</italic>-dealkylation, hydrogenation, mono-oxygenation, hydrolysis, and dehydrogenation, consistent with previous studies [<xref rid="ref13" ref-type="bibr">13</xref>,<xref rid="ref55" ref-type="bibr">55</xref>]. Interestingly, an aldehyde metabolite labelled as an intermediate via <italic toggle="yes">O</italic>-dealkylation, which is responsible for the subsequent hydrogenation to M2 and mono-oxygenation to M3, was not detected in this study. In Cirello&#8217;s study [<xref rid="ref55" ref-type="bibr">55</xref>], &#8220;M10&#8221; (<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 329.0456) has a fragment (<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 255.0081) and the comparison suggests that &#8220;M10&#8221; is equivalent to M2 (<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 329.0454) with its fragment ions (<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 158.9761, 255.0080) of this study. In addition, in Fitch&#8217;s study [<xref rid="ref56" ref-type="bibr">56</xref>], &#8220;M16&#8221; (<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 343.0256) has three fragment ions (<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 159. 275, 255) and the comparison suggests that &#8220;M16&#8221; is equivalent to M3 (<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 343.0247) with its fragment ions (<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 158.9761, 274.9870, 255.0087) of this study. M3 in this study was also identified in Kim&#8217;s work [<xref rid="ref58" ref-type="bibr">58</xref>] as &#8220;M14&#8221; (<italic toggle="yes">m</italic>/<italic toggle="yes">z</italic> 343.0247). In early reports [<xref rid="ref11" ref-type="bibr">11-14</xref>], <italic toggle="yes">N</italic>-deacetyl ketoconazole was also identified as M4, and it possessed a bioactivation function that could potentially be transformed into a cytotoxic agent. However, it was not detected in rat plasma, suggesting that the hepatic toxicity potential is unlikely to occur in rats due to the low systemic concentration after ocular administration. Ketoconazole was a dominant component in the cornea, retina, and vitreous humour. This may suggest a better fit for topical usage in rats and, eventually, in human topical ocular use.</p><fig position="float" id="fig005" orientation="portrait"><label>Figure 5.</label><caption><p>Proposed metabolic pathways of ketoconazole in rat plasma and ocular tissues</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ADMET-12-2387-g005.jpg"/></fig></sec></sec><sec id="sec1-4"><title>Conclusion</title><p>Ketoconazole exhibited higher concentrations in the cornea, retina and vitreous humour than in plasma in rats following single topical ocular administration. The mean ketoconazole concentration in each tissue decreased from 5 to 120 min. The observed metabolic pathways were <italic toggle="yes">O</italic>-dealkylation, mono-oxygenation, and dehydrogenation. Nine metabolites were identified in rat plasma, and the <italic toggle="yes">O</italic>-dealkylated metabolite (M3) and dehydrogenated metabolite (M11) were top two abundant metabolites, accounting for 5.0 and 5.8 % of the total mass abundance, respectively. Eleven metabolites were identified in the rat cornea, and two metabolites were detected in the rat retina and vitreous humour, respectively. The <italic toggle="yes">O</italic>-dealkylated and hydrogenated metabolite (M2) was a dominant metabolite in the cornea, retina, and vitreous humour, while M3 and M11 were the dominant metabolites in plasma. No <italic toggle="yes">N</italic>-deacetyl ketoconazole (M4) was found in the plasma.</p></sec></body><back><ack><title>Acknowledgement</title><p>
<italic toggle="yes">The authors express special thanks to Xiaona Duan, Wenying Sun and Weimin Yuan for their support during sample generation and sample analysis.</italic>
</p></ack><fn-group><fn><p><bold>Ethical statement:</bold>
<italic toggle="yes">All procedures performed on the animals were in accordance with regulations and established guidelines and were reviewed and approved by an Institutional Animal Care and Use Committee through an ethical review process</italic>.</p></fn><fn fn-type="COI-statement"><p><bold>Conflict of interest:</bold>
<italic toggle="yes">The authors have no conflict of interest.</italic></p></fn><fn><p><bold>Funding:</bold>
<italic toggle="yes">None</italic></p></fn></fn-group><ref-list><title>References</title><ref id="ref1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marriott</surname><given-names>M.S.</given-names></name></person-group><article-title>Inhibition of sterol biosynthesis in Candida albicans by imidazole-containing antifungals</article-title>. <source>Journal of General Microbiology</source><volume>117</volume> (<year>1980</year>) <fpage>253</fpage>-<lpage>255</lpage>. <comment>https://doi.org/10.1099/00221287-117-1-253</comment>. <pub-id pub-id-type="doi">10.1099/00221287-117-1-253</pub-id><pub-id pub-id-type="pmid">6993625</pub-id></mixed-citation></ref><ref id="ref2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>D.</given-names></name><name name-style="western"><surname>Drew</surname><given-names>R.</given-names></name><name name-style="western"><surname>Perfect</surname><given-names>J.</given-names></name></person-group><article-title>Expert Review of Anti-infective Therapy infection management Azole antifungals: 35 years of invasive fungal infection management</article-title>. <source>Expert Review of Anti-infective Therapy</source><volume>13</volume> (<year>2015</year>) <fpage>787</fpage>-<lpage>798</lpage>. <comment>http://doi.org/10.1586/14787210.2015.1032939</comment>. <pub-id pub-id-type="doi">10.1586/14787210.2015.1032939</pub-id><pub-id pub-id-type="pmid">25843556</pub-id></mixed-citation></ref><ref id="ref3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larralde</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vivas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Urbina</surname><given-names>J.A.</given-names></name></person-group><article-title>Concentration and time dependence of the effects of ketoconazole on growth and sterol synthesis by Trypanosoma (Schizotrypanum) cruzi epimastigotes</article-title>. <source>Acta Cientifica Venezolana</source><volume>39</volume> (<year>1988</year>) <fpage>140</fpage>-<lpage>146</lpage>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/3075103/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/3075103/</ext-link></comment>.<pub-id pub-id-type="pmid">3075103</pub-id></mixed-citation></ref><ref id="ref4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daneshmend</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Warnock</surname><given-names>D.W.</given-names></name></person-group><article-title>Clinical Pharmacokinetics of Ketoconazole</article-title>. <source>Clinical Pharmacokinetics</source><volume>14</volume> (<year>1988</year>) <fpage>14</fpage>-<lpage>34</lpage>. <comment>http://doi.org/10.2165/00003088-198814010-00002</comment>. <pub-id pub-id-type="doi">10.2165/00003088-198814010-00002</pub-id><pub-id pub-id-type="pmid">3280211</pub-id></mixed-citation></ref><ref id="ref5"><label>[5]</label><mixed-citation publication-type="webpage"><source>Ketoconazole HRA 200 mg tablets. Electronic medicines compendium</source>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.medicines.org.uk/emc/product/1767/smpc" ext-link-type="uri">https://www.medicines.org.uk/emc/product/1767/smpc</ext-link> Accessed November 7, 2024</comment></mixed-citation></ref><ref id="ref6"><label>[6]</label><mixed-citation publication-type="webpage"><source>Drug Development and Drug Interactions Table of Substrates, Inhibitors and Inducers. U.S. Food &amp; Drug</source>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers" ext-link-type="uri">https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers</ext-link> Accessed November 7, 2024</comment></mixed-citation></ref><ref id="ref7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stricker</surname><given-names>B.H.C.</given-names></name><name name-style="western"><surname>Blok</surname><given-names>A.P.R.</given-names></name><name name-style="western"><surname>Bronkhorst</surname><given-names>F.B.</given-names></name><name name-style="western"><surname>Van Parys</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Desmet</surname><given-names>V.J.</given-names></name></person-group><article-title>Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases</article-title>. <source>Journal of Hepatology</source><volume>3</volume> (<year>1986</year>) <fpage>399</fpage>-<lpage>406</lpage>. <comment>http://doi.org/10.1016/S0168-8278(86)80495-0</comment>. <pub-id pub-id-type="doi">10.1016/S0168-8278(86)80495-0</pub-id><pub-id pub-id-type="pmid">3559147</pub-id></mixed-citation></ref><ref id="ref8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Zimmerman</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Benson</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Ishak</surname><given-names>K.G.</given-names></name></person-group><article-title>Hepatic Injury Associated With Ketoconazole Therapy: Analysis of 33 Cases</article-title>. <source>Gastroenterology</source><volume>86</volume> (<year>1984</year>) <fpage>503</fpage>-<lpage>513</lpage>. <comment>http://doi.org/10.1016/S0016-5085(84)80021-9</comment>. <pub-id pub-id-type="doi">10.1016/S0016-5085(84)80021-9</pub-id><pub-id pub-id-type="pmid">6319220</pub-id></mixed-citation></ref><ref id="ref9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banankhah</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Garnick</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Greenblatt</surname><given-names>D.J.</given-names></name></person-group><article-title>Ketoconazole-Associated Liver Injury in Drug-Drug Interaction Studies in Healthy Volunteers</article-title>. <source>Journal of Clinical Pharmacology</source><volume>56</volume> (<year>2016</year>) <fpage>1196</fpage>-<lpage>1202</lpage>. <comment>http://doi.org/10.1002/jcph.711</comment>. <pub-id pub-id-type="doi">10.1002/jcph.711</pub-id><pub-id pub-id-type="pmid">26829173</pub-id></mixed-citation></ref><ref id="ref10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenblatt</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Greenblatt</surname><given-names>D.J.</given-names></name></person-group><article-title>Liver injury associated with ketoconazole: review of the published evidence</article-title>. <source>Journal of Clinical Pharmacology</source><volume>54</volume> (<year>2014</year>) <fpage>1321</fpage>-<lpage>1329</lpage>. <comment>http://doi.org/10.1002/jcph.400</comment>. <pub-id pub-id-type="doi">10.1002/jcph.400</pub-id><pub-id pub-id-type="pmid">25216238</pub-id></mixed-citation></ref><ref id="ref11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Acosta</surname><given-names>D.J.</given-names></name></person-group><article-title>N-deacetyl ketoconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes</article-title>. <source>Toxicology</source><volume>117</volume> (<year>1997</year>) <fpage>123</fpage>-<lpage>131</lpage>. <comment>http://doi.org/10.1016/s0300-483x(96)03560-3</comment>. <pub-id pub-id-type="doi">10.1016/s0300-483x(96)03560-3</pub-id><pub-id pub-id-type="pmid">9057891</pub-id></mixed-citation></ref><ref id="ref12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haegler</surname><given-names>P.</given-names></name><name name-style="western"><surname>Joerin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kr&#228;henb&#252;hl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bouitbir</surname><given-names>J.</given-names></name></person-group><article-title>Hepatocellular Toxicity of Imidazole and Triazole Antimycotic Agents</article-title>. <source>Toxicological Sciences</source><volume>157</volume> (<year>2017</year>) <fpage>183</fpage>-<lpage>195</lpage>. <comment>http://doi.org/10.1093/toxsci/kfx029</comment>. <pub-id pub-id-type="doi">10.1093/toxsci/kfx029</pub-id><pub-id pub-id-type="pmid">28329820</pub-id></mixed-citation></ref><ref id="ref13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Miranda</surname><given-names>C.L.</given-names></name></person-group><article-title>Isoform specificity of N-deacetyl ketoconazole by human and rabbit flavin-containing monooxygenases</article-title>. <source>Drug Metabolism and Disposition</source><volume>28</volume>(<issue>28</issue>) (<year>2000</year>) <fpage>1083</fpage>-<lpage>1086</lpage>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://dmd.aspetjournals.org/content/28/9/1083" ext-link-type="uri">https://dmd.aspetjournals.org/content/28/9/1083</ext-link></comment><pub-id pub-id-type="pmid">10950853</pub-id></mixed-citation></ref><ref id="ref14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiss</surname><given-names>J.</given-names></name><name name-style="western"><surname>Foerster</surname><given-names>K.I.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>M.</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mikus</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lehr</surname><given-names>T.</given-names></name><name name-style="western"><surname>Haefeli</surname><given-names>W.E.</given-names></name></person-group><article-title>Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interaction potential of the parent compound?</article-title><source>European Journal of Pharmaceutical Sciences</source><volume>169</volume> (<year>2022</year>) <fpage>106076</fpage>. <comment>http://doi.org/10.1016/j.ejps.2021.106076</comment>. <pub-id pub-id-type="doi">10.1016/j.ejps.2021.106076</pub-id><pub-id pub-id-type="pmid">34856349</pub-id></mixed-citation></ref><ref id="ref15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenblatt</surname><given-names>D.J.</given-names></name></person-group><article-title>The ketoconazole legacy</article-title>. <source>Clinical Pharmacology in Drug Development</source><volume>3</volume> (<year>2014</year>) <fpage>1</fpage>-<lpage>3</lpage>. <comment>http://doi.org/10.1002/cpdd.100</comment>. <pub-id pub-id-type="doi">10.1002/cpdd.100</pub-id><pub-id pub-id-type="pmid">27128223</pub-id></mixed-citation></ref><ref id="ref16"><label>[16]</label><mixed-citation publication-type="journal"><article-title>Nizoral (Ketoconazole): drug safety communication- potentially fatal liver injury, risk of drug interactions, and adrenal gland problems</article-title>. <source>Clinical Infectious Diseases</source><volume>57</volume> (<year>2013</year>) <fpage>i</fpage>-<lpage>ii</lpage>. <comment>https://doi.org/10.1093/cid/cit548</comment><pub-id pub-id-type="doi">10.1093/cid/cit548</pub-id><pub-id pub-id-type="pmid">24195113</pub-id></mixed-citation></ref><ref id="ref17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lake-Bakaar</surname><given-names>G.</given-names></name><name name-style="western"><surname>Scheuer</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Sherlock</surname><given-names>D.S.</given-names></name></person-group><article-title>Hepatic reactions associated with ketoconazole in the United Kingdom</article-title>. <source>British Medical Journal (Clinical Research Ed.)</source><volume>294</volume> (<year>1987</year>) <fpage>419</fpage>-<lpage>422</lpage>. <comment>http://doi.org/10.1136/bmj.294.6569.419</comment>. <pub-id pub-id-type="doi">10.1136/bmj.294.6569.419</pub-id><pub-id pub-id-type="pmid">3101906</pub-id><pub-id pub-id-type="pmcid">PMC1245420</pub-id></mixed-citation></ref><ref id="ref18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Outeiro</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hohmann</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mikus</surname><given-names>G.</given-names></name></person-group><article-title>No Increased Risk of Ketoconazole Toxicity in Drug-Drug Interaction Studies</article-title>. <source>Journal of Clinical Pharmacology</source><volume>56</volume> (<year>2016</year>) <fpage>1203</fpage>-<lpage>1211</lpage>. <comment>https://doi.org/10.1002/jcph.795</comment>. <pub-id pub-id-type="doi">10.1002/jcph.795</pub-id><pub-id pub-id-type="pmid">27406945</pub-id></mixed-citation></ref><ref id="ref19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hay</surname><given-names>R.J.</given-names></name></person-group><article-title>Ketoconazole: A reappraisal</article-title>. <source>British Medical Journal (Clinical Research Ed.)</source><volume>290</volume> (<year>1985</year>) <fpage>260</fpage>-<lpage>261</lpage>. <comment>http://doi.org/10.1136/bmj.290.6464.260</comment>. <pub-id pub-id-type="doi">10.1136/bmj.290.6464.260</pub-id><pub-id pub-id-type="pmid">3917777</pub-id><pub-id pub-id-type="pmcid">PMC1417545</pub-id></mixed-citation></ref><ref id="ref20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urtti</surname><given-names>A.</given-names></name></person-group><article-title>Challenges and obstacles of ocular pharmacokinetics and drug delivery</article-title>. <source>Advanced Drug Delivery Reviews</source><volume>58</volume> (<year>2006</year>) <fpage>1131</fpage>-<lpage>1135</lpage>. <comment>http://doi.org/10.1016/j.addr.2006.07.027</comment>. <pub-id pub-id-type="doi">10.1016/j.addr.2006.07.027</pub-id><pub-id pub-id-type="pmid">17097758</pub-id></mixed-citation></ref><ref id="ref21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agrahari</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mandal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Agrahari</surname><given-names>V.</given-names></name><name name-style="western"><surname>Trinh</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hadji</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pal</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mitra</surname><given-names>A.K.</given-names></name></person-group><article-title>A comprehensive insight on ocular pharmacokinetics</article-title>. <source>Drug Delivery and Translational Research</source><volume>6</volume> (<year>2016</year>) <fpage>735</fpage>&#8211;<lpage>754</lpage>. <comment>http://doi.org/10.1007/s13346-016-0339-2</comment>. <pub-id pub-id-type="doi">10.1007/s13346-016-0339-2</pub-id><pub-id pub-id-type="pmid">27798766</pub-id><pub-id pub-id-type="pmcid">PMC5319401</pub-id></mixed-citation></ref><ref id="ref22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Durairaj</surname><given-names>C.</given-names></name></person-group><article-title>Ocular pharmacokinetics</article-title>. <source>Handbook of Experimental Pharmacology</source><volume>242</volume> (<year>2017</year>) <fpage>31</fpage>-<lpage>35</lpage>. <comment>http://doi.org/10.1007/164_2016_32</comment>. <pub-id pub-id-type="doi">10.1007/164_2016_32</pub-id><pub-id pub-id-type="pmid">27787714</pub-id></mixed-citation></ref><ref id="ref23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghate</surname><given-names>Deepta</given-names></name><name name-style="western"><surname>Edelhauser Henry</surname><given-names>F.</given-names></name></person-group><article-title>Ocular drug delivery</article-title>. <source>Expert Opinion on Drug Delivery</source><volume>3</volume> (<year>2006</year>) <fpage>275</fpage>-<lpage>287</lpage>. <comment>https://doi.org/10.1517/17425247.3.2.275</comment>. <pub-id pub-id-type="doi">10.1517/17425247.3.2.275</pub-id><pub-id pub-id-type="pmid">16506953</pub-id></mixed-citation></ref><ref id="ref24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horita</surname><given-names>S.</given-names></name><name name-style="western"><surname>Watanabe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Katagiri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nakamura</surname><given-names>H.</given-names></name><name name-style="western"><surname>Haniuda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nakazato</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kagawa</surname><given-names>Y.</given-names></name></person-group><article-title>Species differences in ocular pharmacokinetics and pharmacological activities of regorafenib and pazopanib eye-drops among rats, rabbits and monkeys</article-title>. <source>Pharmacology Research and Perspectives</source><volume>7</volume> (<year>2019</year>) <fpage>487</fpage>-<lpage>527</lpage>. <comment>http://doi.org/10.1002/prp2.545</comment>. <pub-id pub-id-type="doi">10.1002/prp2.545</pub-id><pub-id pub-id-type="pmcid">PMC6864407</pub-id><pub-id pub-id-type="pmid">31763044</pub-id></mixed-citation></ref><ref id="ref25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fayyaz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ranta</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Toropainen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vellonen</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Ricci</surname><given-names>G.D.A.</given-names></name><name name-style="western"><surname>Reinisalo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heikkinen</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>I.</given-names></name><name name-style="western"><surname>Urtti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jamei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Del Amo</surname><given-names>E.M.</given-names></name></person-group><article-title>Ocular Intracameral Pharmacokinetics for a Cocktail of Timolol, Betaxolol, and Atenolol in Rabbits</article-title>. <source>Molecular Pharmaceutics</source><volume>17</volume> (<year>2020</year>) <fpage>588</fpage>-<lpage>594</lpage>. <comment>http://doi.org/10.1021/acs.molpharmaceut.9b01024</comment>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.9b01024</pub-id><pub-id pub-id-type="pmid">31794668</pub-id></mixed-citation></ref><ref id="ref26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fayyaz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vellonen</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Ranta</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Toropainen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Reinisalo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Valtari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Puranen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ricci</surname><given-names>G.D.A.</given-names></name><name name-style="western"><surname>Heikkinen</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ruponen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Urtti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jamei</surname><given-names>M.</given-names></name><name name-style="western"><surname>del Amo</surname><given-names>E.M.</given-names></name></person-group><article-title>Ocular pharmacokinetics of atenolol, timolol and betaxolol cocktail: Tissue exposures in the rabbit eye</article-title>. <source>European Journal of Pharmaceutics and Biopharmaceutics</source><volume>166</volume> (<year>2021</year>) <fpage>155</fpage>-<lpage>162</lpage>. <comment>http://doi.org/10.1016/j.ejpb.2021.06.003</comment>. <pub-id pub-id-type="doi">10.1016/j.ejpb.2021.06.003</pub-id><pub-id pub-id-type="pmid">34139290</pub-id></mixed-citation></ref><ref id="ref27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>del Amo</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Hammid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tausch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Toropainen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sadeghi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Valtari</surname><given-names>A.</given-names></name><name name-style="western"><surname>Puranen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reinisalo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ruponen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Urtti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sauer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Honkakoski</surname><given-names>P.</given-names></name></person-group><article-title>Ocular metabolism and distribution of drugs in the rabbit eye: Quantitative assessment after intracameral and intravitreal administrations</article-title>. <source>International Journal of Pharmaceutics</source><volume>613</volume> (<year>2022</year>) <fpage>121361</fpage>. <comment>http://doi.org/10.1016/j.ijpharm.2021.121361</comment>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.121361</pub-id><pub-id pub-id-type="pmid">34896561</pub-id></mixed-citation></ref><ref id="ref28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>H.</given-names></name></person-group><article-title>Ocular pharmacokinetics of topically-applied ketoconazole solution containing hydroxypropyl beta-cyclodextrin to rabbits</article-title>. <source>Journal of Ocular Pharmacology and Therapeutics</source><volume>24</volume> (<year>2008</year>) <fpage>501</fpage>-<lpage>506</lpage>. <comment>http://doi.org/10.1089/jop.2008.0015</comment>. <pub-id pub-id-type="doi">10.1089/jop.2008.0015</pub-id><pub-id pub-id-type="pmid">18803444</pub-id></mixed-citation></ref><ref id="ref29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dumouchel</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Chemuturi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Milton</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Camenisch</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chastain</surname><given-names>J.</given-names></name><name name-style="western"><surname>Walles</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sasseville</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gunduz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Iyer</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Argikar</surname><given-names>U.A.</given-names></name></person-group><article-title>Models and approaches describing the metabolism, transport, and toxicity of drugs administered by the ocular route</article-title>. <source>Drug Metabolism and Disposition</source><volume>46</volume> (<year>2018</year>) <fpage>1670</fpage>-<lpage>1683</lpage>. <comment>http://doi.org/10.1124/dmd.118.082974</comment>. <pub-id pub-id-type="doi">10.1124/dmd.118.082974</pub-id><pub-id pub-id-type="pmid">30111625</pub-id></mixed-citation></ref><ref id="ref30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Acosta</surname><given-names>D.J.</given-names></name></person-group><article-title>Metabolism of ketoconazole and deacetylated ketoconazole by rat hepatic microsomes and flavin-containing monooxygenases</article-title>. <source>Drug Metabolism and Disposition</source><volume>25</volume> (<year>1997</year>) <fpage>772</fpage>-<lpage>777</lpage>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/9193882/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/9193882/</ext-link></comment>.<pub-id pub-id-type="pmid">9193882</pub-id></mixed-citation></ref><ref id="ref31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamdy</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Brocks</surname><given-names>D.R.</given-names></name></person-group><article-title>Nonlinear stereoselective pharmacokinetics of ketoconazole in rat after administration of racemate</article-title>. <source>Chirality</source><volume>21</volume> (<year>2009</year>) <fpage>704</fpage>-<lpage>712</lpage>. <comment>http://doi.org/10.1002/chir.20669</comment>. <pub-id pub-id-type="doi">10.1002/chir.20669</pub-id><pub-id pub-id-type="pmid">18988259</pub-id></mixed-citation></ref><ref id="ref32"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Remmel</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Amoh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Abdel-Monem</surname><given-names>M.M.</given-names></name></person-group><article-title>The disposition and pharmacokinetics of ketoconazole in the rat</article-title>. <source>Drug Metabolism and Disposition</source><volume>15</volume> (<year>1987</year>) <fpage>735</fpage>-<lpage>739</lpage>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/2893696/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/2893696/</ext-link></comment>.<pub-id pub-id-type="pmid">2893696</pub-id></mixed-citation></ref><ref id="ref33"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamdy</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Brocks</surname><given-names>D.R.</given-names></name></person-group><article-title>The effect of increased lipoprotein levels on the pharmacokinetics of ketoconazole enantiomers in the rat</article-title>. <source>Xenobiotica</source><volume>41</volume> (<year>2011</year>) <fpage>137</fpage>-<lpage>143</lpage>. <comment>http://doi.org/10.3109/00498254.2010.529178</comment>. <pub-id pub-id-type="doi">10.3109/00498254.2010.529178</pub-id><pub-id pub-id-type="pmid">21058917</pub-id></mixed-citation></ref><ref id="ref34"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Von Moltke</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Greenblatt</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Cotreau-Bibbo</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Su Xiang</given-names></name><name name-style="western"><surname>Harmatz</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Shader</surname><given-names>R.I.</given-names></name></person-group><article-title>Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake- inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo</article-title>. <source>Journal of Pharmacology and Experimental Therapeutics</source><volume>268</volume> (<year>1994</year>) <fpage>1278</fpage>-<lpage>1283</lpage>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/8138941/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/8138941/</ext-link></comment>.<pub-id pub-id-type="pmid">8138941</pub-id></mixed-citation></ref><ref id="ref35"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>von Moltke</surname><given-names>L.</given-names></name><name name-style="western"><surname>Greenblatt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cotreau-Bibbo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Harmatz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shader</surname><given-names>R.</given-names></name></person-group><article-title>Inhibitors of alprazolam metabolism in vitro: effect of serotonin- reuptake-inhibitor antidepressants, ketoconazole and quinidine</article-title>. <source>British Journal of Clinical Pharmacology</source><volume>38</volume> (<year>1994</year>) <fpage>23</fpage>-<lpage>31</lpage>. <comment>http://doi.org/10.1111/j.1365-2125.1994.tb04317.x</comment>. <pub-id pub-id-type="doi">10.1111/j.1365-2125.1994.tb04317.x</pub-id><pub-id pub-id-type="pmid">7946933</pub-id><pub-id pub-id-type="pmcid">PMC1364833</pub-id></mixed-citation></ref><ref id="ref36"><label>[36]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Linas</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Malecaze</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bessieres</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Jaureguy</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Mathis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bec</surname><given-names>P.</given-names></name><name name-style="western"><surname>Seguela</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Monbrun</surname><given-names>d&#8217;A A.</given-names></name></person-group><article-title>Etude exp&#233;rimentale de la diffusion intra-oculaire du K&#233;toconazole chez le lapin</article-title>. <source>Medecine et Maladies Infectieuses</source><volume>15</volume> (<year>1985</year>) <fpage>389</fpage>-<lpage>390</lpage>. <comment>http://doi.org/10.1016/S0399-077X(85)80039-1</comment>. <pub-id pub-id-type="doi">10.1016/S0399-077X(85)80039-1</pub-id></mixed-citation></ref><ref id="ref37"><label>[37]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haughey</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Jusko</surname><given-names>W.J.</given-names></name></person-group><article-title>Effect of ketoconazole on methylprednisolone pharmacokinetics and receptor/gene-mediated pharmacodynamics</article-title>. <source>Journal of Pharmacology and Experimental Therapeutics</source><volume>259</volume> (<year>1991</year>) <fpage>826</fpage>-<lpage>832</lpage>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/1941630/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/1941630/</ext-link></comment>.<pub-id pub-id-type="pmid">1941630</pub-id></mixed-citation></ref><ref id="ref38"><label>[38]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bomont</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Tarbit</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Humphrey</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Houston</surname><given-names>J.B.</given-names></name></person-group><article-title>Disposition of Azole Antifungal Agents. II. Hepatic Binding and Clearance of Dichlorophenyl-Bis-triazolylpropanol (DTP) in the Rat</article-title>. <source>Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists</source><volume>11</volume> (<year>1994</year>) <fpage>951</fpage>-<lpage>960</lpage>. <comment>http://doi.org/10.1023/A:1018966800208</comment>. <pub-id pub-id-type="doi">10.1023/A:1018966800208</pub-id><pub-id pub-id-type="pmid">7937554</pub-id></mixed-citation></ref><ref id="ref39"><label>[39]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalgutkar</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Crews</surname><given-names>B.C.</given-names></name><name name-style="western"><surname>Rowlinson</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Marnett</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Kozak</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Remmel</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Marnett</surname><given-names>L.J.</given-names></name></person-group><article-title>Biochemically based design of cyclooxygenase-2 (COX-2) inhibitors: Facile conversion of nonsteroidal antiinflammatory drugs to potent and highly selective COX-2 inhibitors</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>97</volume> (<year>2000</year>) <fpage>925</fpage>-<lpage>930</lpage>. <comment>http://doi.org/10.1073/pnas.97.2.925</comment>. <pub-id pub-id-type="doi">10.1073/pnas.97.2.925</pub-id><pub-id pub-id-type="pmid">10639181</pub-id><pub-id pub-id-type="pmcid">PMC15432</pub-id></mixed-citation></ref><ref id="ref40"><label>[40]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klecker</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Jamis-Dow</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Egorin</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Erkmen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>R.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>J.M.</given-names></name></person-group><article-title>Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat</article-title>. <source>Drug Metabolism and Disposition</source><volume>22</volume> (<year>1994</year>) <fpage>254</fpage>-<lpage>258</lpage>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/7912177/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/7912177/</ext-link></comment>.<pub-id pub-id-type="pmid">7912177</pub-id></mixed-citation></ref><ref id="ref41"><label>[41]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Igarashi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kasuya</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fukui</surname><given-names>M.</given-names></name><name name-style="western"><surname>Usuki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Castagnoli</surname><given-names>N.</given-names></name></person-group><article-title>Studies on the metabolism of haloperidol (HP): The role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following ip administration of HP</article-title>. <source>Life Sciences</source><volume>57</volume> (<year>1995</year>) <fpage>2439</fpage>-<lpage>2446</lpage>. <comment>http://doi.org/10.1016/0024-3205(95)02240-5</comment>. <pub-id pub-id-type="doi">10.1016/0024-3205(95)02240-5</pub-id><pub-id pub-id-type="pmid">8847965</pub-id></mixed-citation></ref><ref id="ref42"><label>[42]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamano</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kotaki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sawada</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Iga</surname><given-names>T.</given-names></name></person-group><article-title>Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: Implication of concentrative uptake of inhibitors into liver</article-title>. <source>Drug Metabolism and Disposition</source><volume>27</volume> (<year>1999</year>) <fpage>395</fpage>-<lpage>402</lpage>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/10064572/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/10064572/</ext-link></comment>.<pub-id pub-id-type="pmid">10064572</pub-id></mixed-citation></ref><ref id="ref43"><label>[43]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ewesuedo</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Dolan</surname><given-names>M.E.</given-names></name></person-group><article-title>Pharmacokinetics of oral O6-benzylguanine and evidence of interaction with oral ketoconazole in the rat</article-title>. <source>Cancer Chemotherapy and Pharmacology</source><volume>46</volume> (<year>2000</year>) <fpage>150</fpage>-<lpage>155</lpage>. <comment>http://doi.org/10.1007/s002800000121</comment>. <pub-id pub-id-type="doi">10.1007/s002800000121</pub-id><pub-id pub-id-type="pmid">10972485</pub-id></mixed-citation></ref><ref id="ref44"><label>[44]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>K.</given-names></name><name name-style="western"><surname>Woolf</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Kindt</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Fielder</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Talaat</surname><given-names>R.E.</given-names></name></person-group><article-title>Troglitazone quinone formation catalyzed by human and rat CYP3A: An atypical CYP oxidation reaction</article-title>. <source>Biochemical Pharmacology</source><volume>62</volume> (<year>2001</year>) <fpage>191</fpage>-<lpage>198</lpage>. <comment>http://doi.org/10.1016/S0006-2952(01)00653-0</comment>. <pub-id pub-id-type="doi">10.1016/S0006-2952(01)00653-0</pub-id><pub-id pub-id-type="pmid">11389877</pub-id></mixed-citation></ref><ref id="ref45"><label>[45]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kotegawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Laurijssens</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Von Moltke</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Cotreau</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Perloff</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Venkatakrishnan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Warrington</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Granda</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Harmatz</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Greenblatt</surname><given-names>D.J.</given-names></name></person-group><article-title>In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat</article-title>. <source>Journal of Pharmacology and Experimental Therapeutics</source><volume>302</volume> (<year>2002</year>) <fpage>1228</fpage>-<lpage>1237</lpage>. <comment>http://doi.org/10.1124/jpet.102.035972</comment>. <pub-id pub-id-type="doi">10.1124/jpet.102.035972</pub-id><pub-id pub-id-type="pmid">12183684</pub-id></mixed-citation></ref><ref id="ref46"><label>[46]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walubo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barr</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Coetsee</surname><given-names>C.</given-names></name></person-group><article-title>The role of cytochrome-P450 inhibitors in the prevention of hepatotoxicity after paracetamol overdose in rats</article-title>. <source>Human and Experimental Toxicology</source><volume>23</volume> (<year>2004</year>) <fpage>49</fpage>-<lpage>54</lpage>. <comment>http://doi.org/10.1191/0960327104ht415oa</comment>. <pub-id pub-id-type="doi">10.1191/0960327104ht415oa</pub-id><pub-id pub-id-type="pmid">15027815</pub-id></mixed-citation></ref><ref id="ref47"><label>[47]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>H.M.</given-names></name></person-group><article-title>Pregnenolone and dexamethasone, modulators of cytochrome P450-3A, not increase but reduce urinary &#945;-CEHC excretion in rats</article-title>. <source>BioFactors</source><volume>31</volume> (<year>2007</year>) <fpage>67</fpage>-<lpage>76</lpage>. <comment>http://doi.org/10.1002/biof.5520310107</comment>. <pub-id pub-id-type="doi">10.1002/biof.5520310107</pub-id><pub-id pub-id-type="pmid">18806310</pub-id></mixed-citation></ref><ref id="ref48"><label>[48]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>X.H.</given-names></name><name name-style="western"><surname>Si</surname><given-names>L.Q.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name></person-group><article-title>Effect of polyoxyl ether analogous surfactants on the activity of cytochromes P450 3A in rats in vivo</article-title>. <source>Yaoxue Xuebao</source><volume>43</volume> (<year>2008</year>) <fpage>528</fpage>-<lpage>534</lpage>. <comment><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://pubmed.ncbi.nlm.nih.gov/18717343/" ext-link-type="uri">https://pubmed.ncbi.nlm.nih.gov/18717343/</ext-link></comment>.<pub-id pub-id-type="pmid">18717343</pub-id></mixed-citation></ref><ref id="ref49"><label>[49]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boralli</surname><given-names>V.B.</given-names></name><name name-style="western"><surname>Coelho</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Lanchote</surname><given-names>V.L.</given-names></name></person-group><article-title>Influence of quinidine, cimetidine, and ketoconazole on the enantioselective pharmacokinetics and metabolism of metoprolol in rats</article-title>. <source>Chirality</source><volume>21</volume> (<year>2009</year>) <fpage>886</fpage>-<lpage>893</lpage>. <comment>http://doi.org/10.1002/chir.20682</comment>. <pub-id pub-id-type="doi">10.1002/chir.20682</pub-id><pub-id pub-id-type="pmid">19161215</pub-id></mixed-citation></ref><ref id="ref50"><label>[50]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sen Cao</surname><given-names>R.</given-names></name><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.F.</given-names></name></person-group><article-title>Effects of triptolide on the pharmacokinetics of cyclophosphamide in rats: A possible role of CytochromeP3A4 inhibition</article-title>. <source>Chinese Journal of Integrative Medicine</source><volume>20</volume> (<year>2014</year>) <fpage>534</fpage>-<lpage>539</lpage>. <comment>http://doi.org/10.1007/s11655-014-1710-0</comment>. <pub-id pub-id-type="doi">10.1007/s11655-014-1710-0</pub-id><pub-id pub-id-type="pmid">24420925</pub-id></mixed-citation></ref><ref id="ref51"><label>[51]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>G.</given-names></name></person-group><article-title>Inhibitory effect of ketoconazole and voriconazole on the pharmacokinetics of carvedilol in rats</article-title>. <source>Drug Development and Industrial Pharmacy</source><volume>41</volume> (<year>2015</year>) <fpage>1661</fpage>-<lpage>1666</lpage>. <comment>http://doi.org/10.3109/03639045.2014.983930</comment>. <pub-id pub-id-type="doi">10.3109/03639045.2014.983930</pub-id><pub-id pub-id-type="pmid">25417773</pub-id></mixed-citation></ref><ref id="ref52"><label>[52]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iida</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sasaki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tsuneyama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fukami</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakajima</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yokoi</surname><given-names>T.</given-names></name></person-group><article-title>Carbamazepine-induced liver injury requires CYP3A-mediated metabolism and glutathione depletion in rats</article-title>. <source>Drug Metabolism and Disposition</source><volume>43</volume> (<year>2015</year>) <fpage>958</fpage>-<lpage>968</lpage>. <comment>http://doi.org/10.1124/dmd.115.063370</comment>. <pub-id pub-id-type="doi">10.1124/dmd.115.063370</pub-id><pub-id pub-id-type="pmid">25870103</pub-id></mixed-citation></ref><ref id="ref53"><label>[53]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name></person-group><article-title>Evaluation of the effects of ketoconazole and voriconazole on the pharmacokinetics of oxcarbazepine and its main metabolite MHD in rats by UPLC-MS-MS</article-title>. <source>Journal of Chromatographic Science</source><volume>54</volume> (<year>2016</year>) <fpage>334</fpage>-<lpage>342</lpage>. <comment>http://doi.org/10.1093/chromsci/bmv146</comment>. <pub-id pub-id-type="doi">10.1093/chromsci/bmv146</pub-id><pub-id pub-id-type="pmid">26499119</pub-id></mixed-citation></ref><ref id="ref54"><label>[54]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name></person-group><article-title>Effect of CYP3A inducer/inhibitor and licorice on hepatotoxicity and in vivo metabolism of main alkaloids of Euodiae Fructus based on UPLC-Q-Exactive-MS</article-title>. <source>Journal of Ethnopharmacology</source><volume>303</volume> (<year>2023</year>) <fpage>116005</fpage> . <comment>http://doi.org/10.1016/j.jep.2022.116005</comment>. <pub-id pub-id-type="doi">10.1016/j.jep.2022.116005</pub-id><pub-id pub-id-type="pmid">36516906</pub-id></mixed-citation></ref><ref id="ref55"><label>[55]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cirello</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Dumouchel</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Gunduz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dunne</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Argikar</surname><given-names>U.A.</given-names></name></person-group><article-title>In vitro ocular metabolism and bioactivation of ketoconazole in rat, rabbit and human</article-title>. <source>Drug Metabolism and Pharmacokinetics</source><volume>32</volume> (<year>2017</year>) <fpage>121</fpage>-<lpage>126</lpage>. <comment>http://doi.org/10.1016/j.dmpk.2016.11.001</comment>. <pub-id pub-id-type="doi">10.1016/j.dmpk.2016.11.001</pub-id><pub-id pub-id-type="pmid">28139372</pub-id></mixed-citation></ref><ref id="ref56"><label>[56]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fitch</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>T.</given-names></name><name name-style="western"><surname>Young</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name></person-group><article-title>Revisiting the Metabolism of Ketoconazole Using Accurate Mass</article-title>. <source>Drug Metabolism Letters</source><volume>3</volume> (<year>2009</year>) <fpage>191</fpage>-<lpage>198</lpage>. <comment>https://doi.org/10.2174/187231209789352085</comment>. <pub-id pub-id-type="doi">10.2174/187231209789352085</pub-id><pub-id pub-id-type="pmid">19799546</pub-id></mixed-citation></ref><ref id="ref57"><label>[57]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Z.</given-names></name></person-group><article-title>Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro</article-title>. <source>Drug Testing and Analysis</source><volume>11</volume> (<year>2019</year>) <fpage>595</fpage>-<lpage>600</lpage>. <comment>http://doi.org/10.1002/dta.2534</comment>. <pub-id pub-id-type="doi">10.1002/dta.2534</pub-id><pub-id pub-id-type="pmid">30370647</pub-id></mixed-citation></ref><ref id="ref58"><label>[58]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>W.G.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.S.</given-names></name></person-group><article-title>Revisiting the metabolism and bioactivation of ketoconazole in human and mouse using liquid chromatography-mass spectrometry-based metabolomics</article-title>. <source>International Journal of Molecular Sciences</source><volume>18</volume> (<year>2017</year>) <fpage>621</fpage>. <comment>http://doi.org/10.3390/ijms18030621</comment>. <pub-id pub-id-type="doi">10.3390/ijms18030621</pub-id><pub-id pub-id-type="pmid">28335386</pub-id><pub-id pub-id-type="pmcid">PMC5372636</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>